Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
ATOS Stock Chart & Stats
$0.62
>-$0.01(-0.49%)
At close: 4:00 PM EST
$0.62
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$0.55 - $1.29
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$88.46M
Enterprise Value$27.78M
Total Cash (Recent Filing)$51.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Apr 01, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding129,171,420
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.66
Price to Sales (P/S)0.00
P/FCF Ratio-5.65
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.47K
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$6.33Price Target Upside920.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2 data showed Z-endoxifen produced a clear efficacy advantage over tamoxifen with improved progression-free survival and a more favorable serious adverse event profile, supporting advancement toward pivotal studies.
Commercial OpportunityEarly RECAST trial results indicating feasibility of a non-surgical approach with Z-endoxifen plus MRI and an overall favorable oral safety profile position endoxifen as a differentiated, potentially scalable alternative for women currently treated with tamoxifen.
Regulatory ProgressFood and Drug Administration feedback on trial design combined with a Rare Pediatric Disease designation for endoxifen in Duchenne muscular dystrophy creates potential for expedited review pathways and a priority review voucher if approval is achieved.
Bears Say
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $0.55 and its highest was $1.29 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $88.46M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 61 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.065 by -$0.005.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 129,171,420 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.065. Following the earnings report the stock price went down -1.693%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (920.97% Upside)
$6.33 (920.97% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.1%
Last 30 Days ▲ 16.0%
Last 30 Days ▲ 16.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.34%
12-Months-Change
Fundamentals
Return on Equity
-48.89%
Trailing 12-Months
Asset Growth
-24.86%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$6.33
▲(920.97% Upside)
Technical Analysis
Ownership Overview
3.41% Insiders
8.74% Mutual Funds
0.03% Other Institutional Investors
83.84% Public Companies and
Individual Investors